Tiziana Life Sciences Ltd.: FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab

This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana

Related Keywords

Boston ,Massachusetts ,United States ,Irina Koffler ,Hana Malik ,Howard Weiner ,Tanuja Chitnis ,Tiziana Life Sciences ,Tiziana Press ,Lifesci Advisors ,Tiziana Life Sciences Ltd ,Drug Administration ,Sclerosis Program ,Study May Proceed Letter ,Institutional Review Board ,Multiple Sclerosis Program ,Scientific Advisory Board ,Neuropsychiatric Dis ,Press Release ,Life Sciences ,Sci Advisors ,Tiziana ,Life ,Ciences ,Migrants ,Permission ,Unenroll ,Dditional ,Secondary ,Progressive ,Multiple ,Clerosis ,Pms ,Patients ,Xpanded ,Access ,Program ,Intranasal ,Foralumab ,